Results of the SPACE trial demonstrating the safety and efficacy of subcutaneous fremanezumab for the prevention of pediatric episodic migraine have now been published.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/fremanezumab-pediatric-migraine-prevention-phase-3-space-2026a10001k2?src=rss
Author :
Publish date : 2026-01-16 11:43:00
Copyright for syndicated content belongs to the linked Source.
